ADVFN Logo ADVFN

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

AZN Astrazeneca Plc

11,994.00
112.00 (0.94%)
14 Mar 2025 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Astrazeneca Plc LSE:AZN London Ordinary Share GB0009895292 ORD SHS $0.25
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  112.00 0.94% 11,994.00 11,994.00 12,000.00 12,018.00 11,854.00 11,860.00 2,284,602 16:29:59
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 54.07B 7.04B 4.5370 26.44 184.24B

AstraZeneca Says Lung Cancer Phase III Trial Didn't Meet Endpoint

09/08/2016 7:58am

Dow Jones News


Astrazeneca (LSE:AZN)
Historical Stock Chart


From Mar 2020 to Mar 2025

Click Here for more Astrazeneca Charts.

LONDON--AstraZeneca PLC (AZN.LN) said on Tuesday the Phase III trial of an inhibitor, selumetinib, in combination with docetaxal chemotherapy to treat lung cancer, didn't meet its main endpoint and that the inhibitor didn't have "significant effect" on overall survival.

Selumetinib is being explored as a treatment option in studies in patients with differentiated thyroid cancer, the company said.

AstraZeneca bought worldwide rights to selumetinib from Array BioPharma Inc. in 2003, it said.

 

Write to Olga Cotaga at olga.cotaga@wsj.com, Twitter @OlgaCotaga

 

(END) Dow Jones Newswires

August 09, 2016 02:43 ET (06:43 GMT)

Copyright (c) 2016 Dow Jones & Company, Inc.

1 Year Astrazeneca Chart

1 Year Astrazeneca Chart

1 Month Astrazeneca Chart

1 Month Astrazeneca Chart